BOULDER, Colo., April 6 /PRNewswire/ -- N30 Pharma today announced the formation of its Scientific Advisory Board, or SAB. The purpose of the SAB is to assist the company in the design and execution of its discovery and development programs across cardiopulmonary medicine and Nitric Oxide (NO) and redox biology. Dr. Joseph Loscalzo, Chairman of the Department of Medicine at Brigham and Women's Hospital and Hersey Professor of the Theory and Practice of Medicine at Harvard Medical School, and a Director of N30 Pharma, will Chair the SAB.
"We have assembled an outstanding group of investigators who bring substantial experience and interest in the key scientific and clinical areas that N30 Pharma targets with its drugs, and we are very pleased that these individuals have elected to join our SAB," Dr. Loscalzo commented.
The new members of the company's SAB include the following clinicians and scientists:
Dr. Augustine Choi, Chief of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Parker B. Francis Professor of Medicine, Harvard Medical School
Dr. Michael Marletta, Chair, Department of Chemistry, Aldo DeBenedictis Distinguished Professor, Joel Hildebrand Distinguished Professor, University of California, Berkeley
Dr. William Sessa, Professor and Vice Chairman, Department of Pharmacology, Director, Vascular Biology and Transplantation Program, Yale University
Dr. Joseph Vita, Professor of Medicine and Cardiology, Boston University
Charles Scoggin, MD, CEO of N30 Pharma, commented on the newly formed SAB. "We are very pleased to work with this group of outstanding researchers. All of us at N30 look forward to the many contributions each will make to the scientific direction and overall development of the company."
Marc Elia, President of N30 Pharma, expects to work closely with the SAB as the company moves forward. "As we move our compounds into human studies, we will look forward to addressing many translational issues with our SAB," Mr. Elia said. "Our goal is to work together to design and execute experiments that demonstrate the substantial potential clinical impact of modulating endogenous Nitric Oxide bioavailability."
About N30 Pharma
N30 Pharma is a cardiopulmonary medicine company focused on the modulation of endogenous Nitric Oxide bioavailability using targeted novel small molecule drugs. The company is headquartered in Boulder, Colorado and New York City, New York.
CONTACT: N30 Pharma, +1-720-945-7700, firstname.lastname@example.org
Web site: http://www.n30pharma.com/